Focal Cryotherapy for Prostate Cancer: a Contemporary Literature Review

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2023 Feb 10

PMID 36760265

Authors

Srinath Kotamarti

Thomas J Polascik

Affiliations

Soon will be listed here.

Abstract

Objective: To perform a comprehensive review of the contemporary literature regarding both functional and oncologic outcomes after primary focal cryotherapy for prostate cancer (PCa), providing these results as a foundation for discussing recent developments in the realm of focal therapy.

Background: Traditional treatments for PCa are often associated with debilitating functional side effects for patients. Due to advances in imaging and biopsy strategies, focal ablative therapies recently have garnered much interest and offer an alternative primary treatment for PCa patients with localized disease. Focal cryoablation utilizes heat extraction from tissues to generate an iceball and cause tissue destruction while sparing uninvolved prostatic regions. Optimized patient selection and postoperative management continue to be areas of interest and study as the field continues to develop.

Methods: A search was performed of the PubMed and Embase databases to identify articles pertaining to primary focal PCa cryoablation since our group's last comprehensive review in 2016.

Conclusions: Primary focal cryoablation for PCa offers optimized functional outcomes and a favorable adverse event profile. True evaluation of oncologic outcomes is hampered by lack of long-term follow-up and highly variable clinical endpoints across these studies. Nonetheless, outcomes appear adequate in the short- to medium-term time frame. Utilization of focal cryoablation is expected to grow with continued refinement of patient selection and management options in cases of treatment failure.

Citing Articles

Focal therapy of prostate cancer: Use of artificial intelligence to define tumour volume and predict treatment outcomes.

Brisbane W, Priester A, Nguyen A, Topoozian M, Mota S, Delfin M BJUI Compass. 2025; 6(1):e456.

PMID: 39877558 PMC: 11771490. DOI: 10.1002/bco2.456.

Cobalt Serum Level as a Biomarker of Cause-Specific Survival among Prostate Cancer Patients.

Pietrzak S, Marciniak W, Derkacz R, Matuszczak M, Kiljanczyk A, Baszuk P Cancers (Basel). 2024; 16(15).

PMID: 39123346 PMC: 11310964. DOI: 10.3390/cancers16152618.

A Comprehensive Review of the Current State of Robot-assisted Laparoscopic Salvage Prostatectomy.

Thakker P, Sandberg M, Hemal A, Rodriguez A Int Braz J Urol. 2024; 50(4):398-414.

PMID: 38701186 PMC: 11262726. DOI: 10.1590/S1677-5538.IBJU.2024.0126.

Primary Total Prostate Cryoablation for Localized High-Risk Prostate Cancer: 10-Year Outcomes and Nomograms.

Chen C, Tsai C, Pu Y Cancers (Basel). 2023; 15(15).

PMID: 37568689 PMC: 10416842. DOI: 10.3390/cancers15153873.

References

Shah T, Peters M, Miah S, Eldred-Evans D, Yap T, Hosking-Jervis F . Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer. Eur Urol Focus. 2019; 7(2):301-308. DOI: 10.1016/j.euf.2019.09.004. View

Buyyounouski M, Choyke P, McKenney J, Sartor O, Sandler H, Amin M . Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67(3):245-253. PMC: 6375094. DOI: 10.3322/caac.21391. View

Wysock J, Becher E, Gogaj R, Velazquez N, Lepor H . Early oncological control following partial gland cryo-ablation: a prospective experience specifying reflex MRI guided biopsy of the ablation zone. Prostate Cancer Prostatic Dis. 2020; 24(1):114-119. DOI: 10.1038/s41391-020-0244-0. View

Tay K, Polascik T, ElShafei A, Tsivian E, Stephen Jones J . Propensity Score-Matched Comparison of Partial to Whole-Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An Analysis of the Cryo On-Line Data Registry Data. J Endourol. 2017; 31(6):564-571. DOI: 10.1089/end.2016.0830. View

Tay K, Amin M, Ghai S, Jimenez R, Kench J, Klotz L . Surveillance after prostate focal therapy. World J Urol. 2018; 37(3):397-407. DOI: 10.1007/s00345-018-2363-y. View

Tan W, Chang A, Sze C, Polascik T . Oncological and Functional Outcomes of Patients Undergoing Individualized Partial Gland Cryoablation of the Prostate: A Single-Institution Experience. J Endourol. 2021; 35(9):1290-1299. PMC: 8558074. DOI: 10.1089/end.2020.0740. View

Lian H, Zhuang J, Yang R, Qu F, Wang W, Lin T . Focal cryoablation for unilateral low-intermediate-risk prostate cancer: 63-month mean follow-up results of 41 patients. Int Urol Nephrol. 2015; 48(1):85-90. DOI: 10.1007/s11255-015-1140-8. View

Werneburg G, Kongnyuy M, Halpern D, Salcedo J, Chen C, LeSueur A . Effects of Focal vs Total Cryotherapy and Minimum Tumor Temperature on Patient-reported Quality of Life Compared With Active Surveillance in Patients With Prostate Cancer. Urology. 2017; 113:110-118. PMC: 5866195. DOI: 10.1016/j.urology.2017.10.054. View

Ashrafi A, Tafuri A, Cacciamani G, Park D, De Castro Abreu A, Gill I . Focal therapy for prostate cancer: concepts and future directions. Curr Opin Urol. 2018; 28(6):536-543. PMC: 9721528. DOI: 10.1097/MOU.0000000000000539. View

10.

Rosen R, Allen K, Ni X, Araujo A . Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol. 2011; 60(5):1010-6. DOI: 10.1016/j.eururo.2011.07.053. View

11.

Beerlage H . Alternative therapies for localized prostate cancer. Curr Urol Rep. 2003; 4(3):216-20. DOI: 10.1007/s11934-003-0072-5. View

12.

Marra G, Soeterik T, Oreggia D, Tourinho-Barbosa R, Moschini M, Filippini C . Long-term Outcomes of Focal Cryotherapy for Low- to Intermediate-risk Prostate Cancer: Results and Matched Pair Analysis with Active Surveillance. Eur Urol Focus. 2021; 8(3):701-709. DOI: 10.1016/j.euf.2021.04.008. View

13.

Gregg J, Borregales L, Choi H, Lozano M, McRae S, Venkatesan A . Prospective trial of regional (hockey-stick) prostate cryoablation: oncologic and quality of life outcomes. World J Urol. 2021; 39(9):3259-3264. PMC: 9810085. DOI: 10.1007/s00345-020-03575-4. View

14.

Rhee H, Thomas P, Shepherd B, Gustafson S, Vela I, Russell P . Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer. J Urol. 2016; 196(4):1261-7. DOI: 10.1016/j.juro.2016.02.3000. View

15.

Polascik T, Mayes J, Mouraviev V . From whole-gland to targeted cryoablation for the treatment of unilateral or focal prostate cancer. Oncology (Williston Park). 2008; 22(8):900-6. View

16.

Wilt T, Brawer M, Jones K, Barry M, Aronson W, Fox S . Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012; 367(3):203-13. PMC: 3429335. DOI: 10.1056/NEJMoa1113162. View

17.

Marra G, Valerio M, Emberton M, Heidenreich A, Crook J, Bossi A . Salvage Local Treatments After Focal Therapy for Prostate Cancer. Eur Urol Oncol. 2019; 2(5):526-538. DOI: 10.1016/j.euo.2019.03.008. View

18.

Habibian D, Katz A . Emerging minimally invasive procedures for focal treatment of organ-confined prostate cancer. Int J Hyperthermia. 2016; 32(7):795-800. DOI: 10.1080/02656736.2016.1195925. View

19.

Benoit R, Naslund M, Cohen J . Complications after prostate brachytherapy in the Medicare population. Urology. 2000; 55(1):91-6. DOI: 10.1016/s0090-4295(99)00122-3. View

20.

Kanthabalan A, Emberton M, Ahmed H . Biopsy strategies for selecting patients for focal therapy for prostate cancer. Curr Opin Urol. 2014; 24(3):209-17. DOI: 10.1097/MOU.0000000000000046. View